Prostate doubling time may be valuable prognostic aid

"It is erdafitinib’s time to shine," says Arlene O. Siefker-Radtke, MD.

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

The reimbursement code for flotufolastat F 18 will be effective October 1, 2023.

To acknowledge the need for increased research funding directed towards women’s health, beyond maternity and reproductive care, AUGS has established the National Urogynecology Research Agenda.